Effect of Acyclovir in COVID-19

Corresponding Author:

Audrey Alice Department of Pharmaceutical sciences, University of Egypt, Egypt E-mail: Alice@yahoo.com

Abstract

Commentary

As of January 1, 2021, the COVID-19 epidemic has redounded in cases worldwide, with nearly of them in the United States alone, and1.8 million deaths worldwide, with about of them having passed in the United States . Health officers first noted COVID-19 and its unproductive agent, SARS-CoV-2( Severe Acute Respiratory Syndrome Coronavirus 2), in Wuhan, China. Original cases had Novel Coronavirus-Infected Pneumonia (NCIP), which persists to this day . COVID-19 cases have also seen severe symptoms like Acute Respiratory Distress Syndrome (ARDS), which causes high situations of mortality . While some cases don’t have similar complications, the unlucky bones with croaker-diagnosed pneumonia, fluidfilled lungs, and ARDS must be rehabilitated, and the number of hospitalizations continues to increase, contributing to an overwhelmed health care system .The National Institutes of Health recommended remdesivir as the only FDA-approved medicine for COVID-19 treatment therefore far. Still, it has also mentioned that treatment plans, including the use of remdesivir, shouldn’t be commanded, and the choice to use it rests with the case and provider . While guidelines promote remdesivir, the medicine has come with mixed issues and a high cost. The medicine lacks a “ demonstrated survival benefit,” and so new developments must be made . Most lately, Louisiana solon-elect Luke Letlow failed at 41 times of age. He was taking remdesivir and corticosteroids. While his condition sounded to ameliorate, the contagion still proved fatal . Chris Long, aPh.D. pupil, returned to the sanitarium after being discharged due to pneumonia, fluid in the lungs, and low oxygen situations, despite ferocious care sweats. Mr. Long is one of conceivably hundreds of thousands of rehospitalizations . Cases in our care have endured the same worsening conditions indeed with remdesivir. Analogues like remdesivir have made patient care precious, while lacking substantial resolution, which necessitates another visit to the sanitarium.

In March 2020, acyclovir was supposed invalid. Since July 2020, our clinic has used acyclovir as a primary antiviral for COVID-19 treatment. Acyclovir is a nucleoside analogue used to treat herpes contagion infections, which is picky to the herpes simplex enzyme thymidine kinase. The medicine inhibits viral DNA polymerase through phosphorylation of the acyclovir emulsion. Acyclovir has been an affordable, safe, and well permitted volition to treating mild-tosevere cases of COVID-19 for our rehabilitated andnon-hospitalized cases. The following cases advance support to this statement.

COVID-19 has been a stomach- churning, disastrous event for all involved in the care of cases since the launch of this epidemic beforehand in the time of 2020. To date, we’ve the use of remdesivir as the antiviral medicine to treat the viral goods on the mortal body from a SARSCoV-2 infection. Fresh medicines employed have been convalescent tube and immunoglobulin products. Monoclonal antibodies have been lately added to a short list of approved rectifiers for the treatment of cases with SARS-CoV-2 who are at elevated threat for hospitalization. Corticosteroids, specifically 6 mg of dexamethasone daily for 10 days has been recommended for mechanically voiced cases for those taking supplemental oxygen remedy. Colourful intravenous and oral antibacterial composites have come standard prophylaxis treatments for rehabilitated cases.